Brain Abnormality in Modern Humans Linked to Ancient Neanderthal DNA
The study focuses on Chiari malformation type I (CM-I), where the lower part of the brain extends too far into the spinal cord – typically linked to having a smaller-than-normal occipital bone at the back of the skull. It can lead to headaches, neck pain, and more serious conditions, and is thought to affect up to 1 in 100 people.
Several other ancient human species had different skull shapes to our own, and a previous study published in 2013 put forward the idea that interbreeding between Homo sapiens and these other hominins may be a root cause of Chiari malformation type I (CM-I), the mildest type of the group.
Related:
Now, a team led by osteoarchaeologist Kimberly Plomp from the University of the Philippines has tested this hypothesis. "The legacy of these interbreeding events can be identified in the genomes of many living humans," the researchers write.
The researchers used 3D modeling and shape analysis techniques to compare 103 skulls of people today with and without CM-I, and 8 fossil skulls from ancient species, including Homo erectus, Homo heidelbergensis, and Homo neanderthalensis (Neanderthals).
People with CM-I had differences in skull shape, the analysis showed, including the area where the brain connects to the spine. However, these skull shapes weren't similar to all of the ancient hominins studied – only to Neanderthals.
In fact, skulls from H. erectus and H. heidelbergensis were more similar to the skulls of modern humans without CM-I. As a result, the researchers suggest the original hypothesis was too broad, and should be adapted to look specifically at Neanderthal links.
"Rather than the genes being traceable to H. erectus, H. heidelbergensis, and H. neanderthalensis, our results are consistent with them being traceable just to H. neanderthalensis," write the researchers.
The study team proposes a Neanderthal Introgression Hypothesis to replace the one formed in 2013. It adds to a growing body of evidence around how early Homo sapiens and Neanderthals mingled, interbreeded, and exchanged genetic information.
Next, the researchers are keen to expand the sample used in their analysis – in terms of both modern and ancient skulls, and across ages – which should tell us more about the relationship between CM-I skull structures and skulls in these early peoples.
The hypothesis also needs to be put to the test in groups of people from different parts of the world. We know that African populations have less Neanderthal DNA than populations in Europe and Asia, which should be reflected in cases of CM-I.
Ultimately, these findings and the techniques used to reach them could help inform ways of treating Chiari malformations or perhaps stopping them from happening in the first place – although it's likely there are several causes for the condition, including genetics.
"The methods would seem to have the potential to help us develop a deeper understanding of the aetiology and pathogenesis of Chiari malformations, which could in turn strengthen diagnosis and treatment of the condition," write the researchers.
The research has been published in Evolution, Medicine, and Public Health.
One Piece of Advice to Parents Slashed Food Allergies in Children
Mondayitis Could Have a Deadly Effect On Your Body
Cannabis Use Is Linked to Epigenetic Changes, Scientists Discover
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Health Line
2 hours ago
- Health Line
Understanding the Types of Multiple Myeloma
Key takeaways The types of active multiple myeloma are categorized by the overproduced immunoglobulin, with IgG being the most common and IgE the rarest and most aggressive. Smoldering multiple myeloma is a precancerous condition without symptoms that can progress to active myeloma, requiring monitoring but not always immediate treatment. Multiple myeloma is a cancer of the plasma cells. Plasma cells are found in the bone marrow. They help your body produce immune system proteins, also known as immunoglobulins or antibodies, that target and destroy pathogens. Pathogens are disease-causing organisms. With multiple myeloma, plasma cells multiply too quickly. They overproduce an irregular protein called a monoclonal protein (M protein). Unlike a healthy immune system antibody, this protein cannot fight pathogens. Common symptoms of myeloma include bone pain, fatigue, and nausea, but not everyone experiences them. This article overviews multiple myeloma types and subtypes and their features. Smoldering vs. active multiple myeloma Smoldering multiple myeloma (SMM) is a precancerous condition that can develop into multiple myeloma over time. People with SMM don't have symptoms, so they're not likely to know they have it. Indeed, most cases are detected incidentally. For example, a doctor might notice increased protein levels during a routine blood or urine test and discover SMM upon further testing. If you have SMM, you may not require any treatment. A doctor might suggest regular monitoring to look for signs of your condition progressing to active myeloma. How often does smoldering multiple myeloma become active? Most cases of SMM eventually progress to active multiple myeloma. According to research cited in a 2022 article: SMM carries a 50% risk of progressing to myeloma within 5 years. SMM carries a 65% risk of progressing to myeloma within 10 years. About 25% of people with SMM never develop myeloma symptoms. Still, the risk can vary a lot from person to person. Higher M protein levels and bone marrow plasma cell percentages carry a higher risk of progression to myeloma within a few years. Types of active multiple myeloma In contrast to healthy plasma cells, myeloma cells only produce one type of immunoglobulin, resulting in a surplus of that type. Myeloma is categorized according to the type of immunoglobulin that's overproduced. There are five types: IgG myeloma: This is the most common type. In a 2020 study including 8,468 people with myeloma, about 57% had IgG. IgA myeloma: In the same study, IgA accounted for 20% of myeloma cases. According to 2020 research, IgA may have lower long-term survival rates than IgG. IgM myeloma: While similar to IgG and IgA, this type is much rarer, making up only 1% of myeloma cases. Overproduction of IgM usually develops into other disorders, like Waldenstrom macroglobulinemia. IgD myeloma: This rare type accounts for less than 2% of myeloma cases. It's more common in males and more likely to start at a younger age. It's typically more aggressive. IgE myeloma: Only 0.1% of myeloma cases are IgE, making it the rarest type. It's more aggressive than other types and has lower survival rates. Light-chain myeloma Light-chain myeloma is the third most common type of multiple myeloma after IgG and IgA. It makes up about 15% of myeloma cases, according to a 2018 review. The term 'light chain' refers to the structure of immunoglobulins, which have two larger heavy chains and two smaller light chains. In light-chain myeloma, myeloma cells produce incomplete immunoglobins that do not have heavy chains. They only have light chains, also known as Bence-Jones proteins. Nonsecretory myeloma Nonsecretory myeloma is a rare form of myeloma that accounts for around 3–5% of cases. It occurs when cancerous myeloma cells are present in the bone marrow but don't make or release any immunoglobulins. This type of myeloma is sometimes more challenging to detect since it doesn't cause elevated levels of immunoglobulins in urine or blood. Doctors may use bone marrow scans, such as CT scans or PET scans, to make a diagnosis. Related plasma chain disorders Myeloma is a type of plasma chain or plasma cell disorder. That means it affects plasma cells' ability to produce immunoglobulins or antibodies. Related plasma chain disorders include: MGUS Monoclonal gammopathy of undetermined significance (MGUS) is a relatively common condition in which M proteins are present in your blood without affecting your health. Different countries have reported MGUS rates ranging from 0.05–6.1%. It's more common among certain groups, such as older adults and Black people. MGUS doesn't usually cause symptoms. Only around 1% of people who have it go on to develop active myeloma each year. Doctors typically suggest monitoring MGUS with regular blood tests. Solitary plasmacytoma A plasmacytoma is a plasma cell tumor. Most plasma cell tumors, including myeloma tumors, grow in the bone marrow. Multiple myeloma causes many tumors in bone marrow all over the body. In contrast, solitary plasmacytoma only causes one tumor. Because solitary plasmacytoma is limited to a single area, it's easier to treat. Doctors can usually remove the tumor via radiation, surgery, or both. Extramedullary plasmacytoma Extramedullary plasmacytoma occurs when a single plasma cell tumor grows in soft tissue rather than bone. In a 2022 study, 62% of these tumors were in the head and neck area. As with solitary plasmacytoma, the cancer is localized to a single area, and treatment with radiation or surgery is usually effective. Light-chain amyloidosis Light-chain amyloidosis is when light-chain proteins produced by abnormal plasma cells accumulate throughout the body. These deposits, known as amyloid deposits, can lead to organ damage. This condition can occur independently of myeloma cancer. However, it can also be a complication of multiple myeloma. Waldenstrom macroglobulinemia Waldenstrom macroglobulinemia (WM) is a rare form of cancer that shares features in common with multiple myeloma. WM cells overproduce IgM, an M protein that's sometimes overproduced in myeloma. Despite this similarity, experts classify WM as a type of non-Hodgkin's lymphoma because it affects the lymphatic system. Hyperdiploid vs. hypodiploid myeloma Doctors sometimes classify multiple myeloma tumors according to the number of chromosomes found in tumor cells: Hyperdiploid myeloma tumors have 47–74 chromosomes. Hypodiploid myeloma tumors have 44 or fewer chromosomes. The authors of a 2021 case report cite research suggesting that hyperdiploid multiple myeloma is typically less aggressive than the hypodiploid type. Frequently asked questions What is the most common type of multiple myeloma? Accounting for more than 50% of all myelomas, IgG is the most common type of multiple myeloma. The next most common types are IgA and light-chain myeloma. What is the most aggressive type of multiple myeloma? According to a 2020 study, IgA and light-chain myeloma are associated with poorer overall survival than other common types. The median overall survival was 4.7 years after diagnosis for people with IgA myeloma and 4.8 years after diagnosis for people with light-chain myeloma. The Canadian Cancer Society reports that IgE is the most aggressive type of myeloma. However, it is extremely rare. What is the difference between kappa and lambda multiple myeloma? Kappa and lambda are two types of light chains. In multiple myeloma, one or the other may be overproduced. According to a 2017 study, myeloma with lambda light chains carries a poorer overall outlook. Takeaway Multiple myeloma is a cancer that causes uncontrolled plasma cell growth. The hallmark of myeloma is the presence of M proteins in blood or urine. The type of M protein overproduced determines the type of myeloma.
Yahoo
3 hours ago
- Yahoo
Strategic Collaborations and Local Innovations Reshape the $24.58 Billion Market
The Asia Pacific diabetes market is set for growth, expected to expand annually by 8.8% to reach $24.58 billion by 2025. Significant trends include increased diabetes prevalence and digital health adoption, driving demand for monitoring and therapeutic solutions. Enhanced policy reforms and insurance coverage are fostering market access, while rising competition is reshaping the landscape with strategic alliances and localized innovation. The comprehensive report analyzes diagnosis and monitoring devices and therapeutics, exploring market dynamics and opportunities. Get insights on the competitive environment, segment growth, and investment potential within the diabetes market in Asia Pacific. Asia-Pacific Diabetes Devices and Therapeutics Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in Asia Pacific is expected to grow by 8.8% on annual basis to reach US$24.58 billion in 2025. The diabetes market in the region has experienced robust growth during 2020-2024, achieving a CAGR of 9.4%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.4% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 22.59 billion to approximately USD 35.43 billion. This report provides a detailed data-centric analysis of the diabetes industry in Asia Pacific, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. The market features participation from both established multinational corporations and emerging regional manufacturers. The competitive environment is characterized by varied regulatory frameworks and economic conditions across the Asia Pacific. Publications from the past 12 months indicate a segmented market with regional differentiation in product offerings and market strategies. The market is evolving with a mix of longstanding multinational entities and agile local innovators. With an expected trend toward consolidation and strategic collaborations, the next 2-4 years will likely see a reshaping of competitive dynamics focused on localized product innovation and regulatory alignment. The diabetes devices and therapeutics market in Asia Pacific is being reshaped by increased diabetes prevalence, the adoption of digital health solutions, and evolving policy frameworks. These drivers are expected to intensify over the next 2-4 years, leading to more targeted and data-supported approaches in managing diabetes across diverse regional Rising Diabetes Prevalence and Healthcare Demand Recent publications (2023-2024) report a measurable increase in diabetes cases across Asia Pacific, with significant examples in China, India, and several Southeast Asian nations. Rising incidences of type 2 diabetes are increasing the need for effective monitoring and therapeutic interventions. Demographic shifts (aging populations, urbanization) and evolving lifestyle patterns drive the demand. Adjustments in healthcare financing and insurance reforms across the region support wider access to diagnostic devices and therapies. Anticipate a steady intensification in demand for devices that integrate daily management tools. Healthcare systems will likely expand investments in diabetes-related technologies to address the growing burden. Leverage Digital Integration and Remote Monitoring Solutions Recent regional studies highlight the increased adoption of continuous glucose monitoring (CGM) systems and telehealth services, especially in Japan and South Korea. Various Asia Pacific markets have initiated pilot programs integrating remote monitoring with traditional care models. Technological progress and supportive regulatory policies in digital health are key drivers. Increased investments in digital infrastructure by governments and insurers foster the adoption of connected devices. Expect further penetration of digital health solutions, with remote monitoring playing a more central role in clinical decision-making. Enhanced data analytics are likely to support more personalized diabetes management strategies regionally. Activate Policy Reforms and Insurance Coverage Enhancements Recent reforms in countries like Singapore and Australia have expanded reimbursement for diabetes management devices. Publications from late 2023 detail shifts in regulatory frameworks that now favor broader insurance coverage for innovative therapeutics. Government initiatives focused on reducing long-term healthcare expenditures and improving chronic disease management drive policy changes. Broader insurance reforms align with healthcare objectives to support preventive care and early intervention. The convergence of supportive policies and insurance incentives will further facilitate market access for new devices and therapies. Ongoing regulatory clarifications will likely encourage domestic and international investments in the region. Map Key Players and New Entrants Major global companies continue investing in research and development to maintain their regional presence. Local manufacturers, particularly in India and China, are entering the market with products tailored to regional cost structures and clinical needs. New entrants are leveraging localized expertise to address gaps in the current market, supported by regional demand for cost-effective solutions. Evaluate Strategic Collaborations and Market Consolidation Recent transactions in the last 12 months have seen collaborations between device manufacturers and healthcare providers in Southeast Asia and Australia. Strategic alliances emerge as companies seek to expand their product portfolios and market reach through mergers and acquisitions. The competitive landscape will likely experience increased consolidation as larger players acquire or partner with regional innovators. Firms that successfully navigate regulatory requirements and invest in localized development are positioned to gain competitive advantages. Forecast Competitive Shifts Continued regulatory reforms and heightened demand for diabetes management solutions will attract further competition. Specialized product developments addressing country-specific needs may lead to a more segmented competitive environment. Investment in research, strategic partnerships, and adaptation to local regulatory environments will be critical for sustaining market leadership. A bundled offering, combining the following 12 reports, covering 480 tables and 648 figures: Asia Pacific Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Australia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) China Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) India Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Indonesia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Japan Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Malaysia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Philippines Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Singapore Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) South Korea Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Taiwan Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Thailand Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Scope for Each Report Diabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare Reasons to buy Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user. Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly. Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation. Key Attributes: Report Attribute Details No. of Pages 840 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $26.63 Billion Forecasted Market Value (USD) by 2029 $35.43 Billion Compound Annual Growth Rate 7.4% Regions Covered Asia Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio